Han M, et al. - Researchers sought to assess the response of metaplastic breast carcinoma to neoadjuvant chemotherapy. They tested various clinical-pathologic variables for association with survival in metaplastic breast carcinoma cases diagnosed between 2007 and 2017. Median age at diagnosis with metaplastic breast carcinoma was 64 years. Similar to other breast cancer subtypes, tumor size and lymph node status had prognostic value in metaplastic carcinomas. Compared to previous reports, this study reported a higher pathologic complete response rate (17%) of metaplastic breast carcinoma. Despite an association of the matrix-producing subtype with pathologic complete response, they identified no survival difference with respect to tumor subtypes.